Feb 23 2009
MedX Health Corp., (TSXV.MDX) a global leader in developing drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced that the company has received a Notice of Allowance by the United States Patent + Trademark Office for its MedX Laser and Light Probe use and method for bone healing, bone growth stimulation and bone cartilage regeneration. The allowed claims cover the use of MedX's laser and light unit and the use of light therapy in various bone and cartilage healing situations such as carpal tunnel syndrome, tendonitis, bone growth and regeneration following a break, rheumatoid arthritis and wound healing.
"This notice of allowance from the U.S. Patent & Trademark Office broadens our device portfolio," states Steve Guillen, president and CEO of MedX Health. "It is another important step toward our entry into the wound healing market, which we expect will take place this year," adds Guillen.
The use of low level lasers and light therapy has been documented to be effective in promoting healing of bone, muscle, cartilage, tendon and ligaments. The newly allowed claims will cover The MedX Laser and Light Probe and its use in the treatment of damaged bone and cartilage. Specifically, the probe emits light, which triggers biological changes within the body, stimulating and accelerating cellular metabolic processes. The process of utilizing the MedX Laser and Light Probe increases the circulation by formulating new capillaries, and also stimulates collagen protein production, thus accelerating the healing process by helping damaged bone cells and tissue replace themselves more rapidly.